Shots:
- Health Canada has approved Andembry (garadacimab) for HAE pts (≥12yrs)
- Approval was based on P-III (VANGUARD) trial assessing Andembry (n=39) vs PBO (n=25) for 6mos., which showed 62% pts remained attack-free, with reduction in overall HAE attacks by >99% median & 89.2% mean; data was published in The Lancet
- Interim analysis of the ongoing OLE study, with a median Andembry exposure of 13.8mos., demonstrated favorable long-term safety & sustained reductions in HAE attacks; data was published in Allergy
Ref: Newswire.CA | Image: CSL | Press Release
Related News:- CSL Receives the US FDA Approval for Andembry as a Prophylactic Treatment of Hereditary Angioedema (HAE)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
